UCB Share Price Other OTC
Stocks
UCBJF
BE0003739530
Pharmaceuticals
OTC Markets Traded| Market Cap | 45.55B 52.13B 42.04B 38.75B 73.03B 5,020B 74.65B 502B 198B 2,459B 196B 191B 8,463B | P/E 2026 * |
25.6x | P/E 2027 * | 20.4x |
|---|---|---|---|---|---|
| Enterprise Value | 45.31B 51.85B 41.81B 38.54B 72.64B 4,993B 74.25B 500B 197B 2,445B 195B 190B 8,418B | EV / Sales 2026 * |
5.3x | EV / Sales 2027 * | 4.48x |
| Free-Float |
61.59% | Yield 2026 * |
0.61% | Yield 2027 * | 0.63% |
Last Transcript: UCB
| 1 day | -0.39% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 31/12/2014 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 59 | 30/06/2020 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 30/04/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 31/12/2011 | |
| Director/Board Member | 67 | 31/12/2014 | |
| Director/Board Member | 56 | 23/04/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.39% | -.--% | - | - | 52.13B | |
| -0.33% | +1.83% | +24.73% | -6.86% | 68.85B | |
| +0.94% | +39.60% | +39.60% | +39.60% | 43.46B | |
| +1.12% | +0.35% | -52.09% | -53.39% | 41.24B | |
| -1.40% | +3.43% | +64.81% | -25.41% | 30.41B | |
| -2.11% | -9.45% | +97.76% | -49.58% | 24.53B | |
| +0.51% | +0.46% | +72.78% | +90.09% | 23.42B | |
| -5.57% | -0.84% | -0.11% | +182.38% | 19.75B | |
| -0.86% | -1.99% | +70.03% | +117.01% | 16.57B | |
| +1.34% | -5.25% | +74.97% | +150.25% | 15.95B | |
| Average | -0.68% | -1.49% | +43.61% | +49.34% | 31.58B | |
| Weighted average by Cap. | -0.42% | -0.54% | +34.15% | +25.01% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.54B 9.78B 7.88B 7.27B 13.7B 941B 14B 94.23B 37.06B 461B 36.71B 35.91B 1,587B | 9.64B 11.04B 8.9B 8.2B 15.46B 1,063B 15.8B 106B 41.84B 520B 41.44B 40.53B 1,792B |
| Net income | 1.77B 2.03B 1.63B 1.51B 2.84B 195B 2.9B 19.52B 7.68B 95.53B 7.61B 7.44B 329B | 2.28B 2.61B 2.1B 1.94B 3.65B 251B 3.73B 25.12B 9.88B 123B 9.79B 9.57B 423B |
| Net Debt | -242M -277M -224M -206M -388M -26.69B -397M -2.67B -1.05B -13.07B -1.04B -1.02B -45B | -2.32B -2.66B -2.14B -1.98B -3.72B -256B -3.81B -25.62B -10.08B -125B -9.98B -9.76B -432B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
